Shire & Baxalta Seal The Deal
Shire PLC and Baxalta Inc. shareholders have both voted in favor of the latter's sale to rare disease focused Shire for a price tag of $32bn – closing an almost year-long deal discussion.
You may also be interested in...
As Takeda discloses that it is considering making a bid to acquire Shire, other big pharma companies look likely to assess their own interest in the firm. Pfizer and AbbVie are among those that may lay their cards on the table.
Immunology portfolio yielded 14% sales growth in 2017, led by growing subcutaneous immunoglobulins and a still-rising HAE franchise. Dry eye drug Xiidra was another 2017 growth catalyst.
Fourth-quarter earnings reports from J&J, Novartis, AbbVie and Biogen all missed on sales but more worryingly, lower sales from some recent acquisitions contributed to the missed expectations. The time from child star to problem child seems to be shorter than I remember.